Table 3.

Association of PTGS2 rs5275 SNP with invasive ovarian carcinoma risk by histology

Subgroups by histology	No. (%) cases by histology Total N=987			Heterozygotes and rare allele homozygotes*			Log-additive model		Recessive model
	TT	TC	CC	TC OR (95% CI)†	CC OR (95% CI)†	P (2 d. f.)	Per allele OR (95% CI)†	P (1 d.f.)	CC vs. TT+TC OR (95% CI)†	P (1 d.f.)
Serous (n=533)	247 (46)	225 (42)	61 (12)	1.04 (0.83-1.29)	1.05 (0.75-1.47)	0.93	1.03 (0.88-1.20)	0.72	1.03 (0.75-1.42)	0.86
Endometrioid (n=201)	104 (52)	80 (40)	17 (8)	0.92 (0.67-1.27)	0.70 (0.40-1.21)	0.43	0.87 (0.69-1.09)	0.23	0.72 (0.43-1.23)	0.23
Clear cell (n=130)	64 (49)	56 (43)	10 (8)	1.03 (0.71-1.52)	0.72 (0.36-1.44)	0.59	0.92 (0.69-1.72)	0.56	0.71 (0.36-1.39)	0.31
Mucinous (n=79)	45 (57)	28 (35)	6 (8)	0.81 (0.50-1.33)	0.68 (0.28-1.66)	0.56	0.82 (0.57-1.18)	0.29	0.75 (0.32-1.77	0.51
Other (n=44)	21 (48)	22 (50)	1 (2)	1.45 (0.78-2.69)	0.23 (0.03-1.75)	0.13	0.92 (0.72-1.18)	0.52	0.57 (0.30-1.09)	0.09
All nonserous (n=454)	234 (52)	186 (41)	34 (7)	0.99 (0.79-1.24)	0.66 (0.44-0.99)	0.12	0.88 (0.75-1.04)	0.13	0.66 (0.44-0.98)	0.04
P‡ heterogeneity: serous versus nonserous tumors				0.91	0.07		0.12		0.07
P‡ heterogeneity: among nonserous tumors				0.96	1.00		0.96		1.00

Note: histology was not available for 38 cases

^*TT genotype was used as the reference group

^†ORs and 95% CIs adjusted for age, ethnicity, education, family history of breast and/or ovarian cancer, menopausal status, use of contraceptive and menopausal hormones, and study

^‡Heterogeneity of associations of the rs5275 genenotype with risk by histological type was evaluated using the Wald test comparing ORs across subgroups by histology in polytomous logistic regression models

Note: statistically significant estimates (p < 0.05) are presented in bold font